Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.
about
Management of HCV-Associated Liver Cirrhosis.Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspectiveRecent Advances in Antiviral Therapy for Chronic Hepatitis CKASL clinical practice guidelines: management of hepatitis CExceptional Heterogeneity in Viral Evolutionary Dynamics Characterises Chronic Hepatitis C Virus InfectionDesirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We NeedAntiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphomaClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CInterferon-free combination therapies for the treatment of hepatitis C: current insightsIndian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Hepatitis C treatment: where are we now?New Therapies for Hepatitis C Virus Infection.Hepatitis C in a New Era: A Review of Current TherapiesCost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in IndiaLethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from BelgiumTreatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspectiveChronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment StrategiesSequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6.CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and TreatmentSASLT guidelines: Update in treatment of Hepatitis C virus infection.The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations.Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.Why I do not treat patients for mild disease.In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor LedipasvirSafety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C.Successful Treatment of Mixed Hepatitis C Genotypes in a Cirrhotic Patient With an All-Oral, Interferon-Free RegimenUpdate on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients.Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions.Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature.Hepatitis C virus genotype 4: Genotype 1's little brother.Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.Urgency to treat patients with chronic hepatitis C in Asia.Hepatitis C virus management: potential impact of nanotechnology.Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016.Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.
P2860
Q26740320-8D026E3C-8D28-4E49-9323-40A628D4C85AQ26746910-2C377DFE-4FC9-4C65-8A47-EADBDDF544C2Q26750476-AD03B1C4-8118-49A6-9EC3-96172AEB7C59Q26752471-10C589CD-41F5-40B3-A030-8F703979948AQ27468696-811B4557-34F3-48C7-9ED2-38107F9C0B5BQ28067411-AD11BB0C-6991-4D6D-86C2-76CC2E5D0EADQ28080160-07594865-A08D-4756-A32E-F0D44DF225B1Q28080225-B2E21ABB-1C2A-4B80-B287-D6B351F87E30Q28087400-C5D8F2E8-13EE-42B2-8988-9F352E947CE1Q30355190-CC0DFA88-D012-435A-9CE0-5949A47EE05AQ30378509-C478313A-57C3-45CF-9A2C-41466AAC375FQ33560181-4105467C-C1E8-4C1D-86CD-F7B8C8EFE64FQ33585021-5ADBAF20-A9A8-4014-BA5F-035D29854E2EQ33698956-3D787EC4-A051-4984-A9B6-F6BDCA22268FQ36166222-CCDED999-8202-4833-B05C-A59ED1AE77BEQ36261373-9FEF99F1-D061-4188-8BFA-5725507D14DDQ36519126-921D1789-708E-4A82-AB5F-8576A45BB7FCQ36870118-2AFB00F2-7D15-4233-A4C8-C748BD916C8DQ36981033-2DF494CE-1814-4C99-A7D3-F05FACFAF78FQ37040485-E08B3A13-37D2-45B7-BFAF-9698FA30D600Q37100669-307683D4-872B-41FE-825D-A8D529F6FFE1Q37216507-D6AFCDF4-3FC6-4EB7-8CED-CB37DD667B00Q37555313-AC9CCDE7-65A5-4914-9537-817C05808D54Q38602682-8C8E8A0A-467A-4C3D-8E64-564470465744Q38685566-CEB62D82-44A3-4DC0-B708-D490752989F4Q38740523-58338B35-30A0-4A69-98E3-C4A505ECF657Q38742966-A6A3FCB0-8C18-4B92-A26F-3342B6EA30F9Q38863925-2B4AE88F-5EBE-433F-8452-2596A02C8110Q38880996-74374B32-C082-4EDF-A0D0-FC0D4FB220E8Q38893128-A69EFEB7-3730-4493-9F13-5982A38F5D96Q38893244-BD431DC0-847E-4384-83AB-0C361F0A5A62Q38927205-F3144D30-5FF8-4481-925D-163F1899930CQ38959188-1C6821CB-219B-4DCE-BA71-F14C7EDD4728Q39025320-551B05C3-8144-4FD9-A7AC-7B168AFE12D6Q39032538-4BFBB329-2CF4-44C6-84EA-0703FCD3B091Q39049155-8E19AD91-3C4D-40A4-A16F-EB2743DEC9E7Q39278958-891A768B-F76B-45FE-8452-A000AC2E45D6Q40211449-8863E322-52BF-4EC0-8EFE-33B131D71D20Q40292229-2BA39750-9DD4-4B93-9378-CDFB786D872CQ40466129-FCB42110-E78C-4FB1-B7BB-7BA8EE4C4F9B
P2860
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.
@ast
Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.
@en
type
label
Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.
@ast
Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.
@en
prefLabel
Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.
@ast
Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.
@en
P2093
P2860
P1476
Ledipasvir and sofosbuvir for ...... n-label phase 2a cohort study.
@en
P2093
Amy Nelson
Anita Kohli
Anu Osinusi
Chloe Gross
Colleen Kotb
Gebeyehu Teferi
Henry Masur
Kate Sugarman
Michael A Polis
P2860
P304
P356
10.1016/S1473-3099(15)00157-7
P577
2015-07-14T00:00:00Z